Added to YB: 2026-08-04
Pitch date: 2026-07-31
MYX.AX [bullish]
Mayne Pharma Group Limited
+4.64%
current return
Author Info
Raper Capital has 20+ years of buy- and sell-side experience in a variety of roles, and currently manage my single family office, Raper Capital Sign up for the newsletter.
Company Info
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.
Market Cap
AUD 216.1M
Pitch Price
AUD 2.80
Price Target
7.50 (+156%)
Dividend
N/A
EV/EBITDA
6.32
P/E
-2.56
EV/Sales
0.47
Sector
Pharmaceuticals
Category
special_situation
Mayne Pharma (MYX.AX) – a break-up (and a double) hiding in plain sight?
MYX.AX (new position): Broken A$7.40 Cosette deal left ASX-listed US pharma (women's health, derm) at A$2.50, ~3.6x FY25 EBITDA vs 11x takeout. FY26 EBITDA A$31.7mm (-33%) but ~A$100mm to acquirer via synergies. 20% register now activist funds (Funicular, Rubric, Trium). Break-up SoTP $6-7.50; downside $2.80 floor + Salisbury sale/buyback. Author engaging mgmt. Risks: appeal, timeline, operating.
Read full article (16 min)